MedTrace Logo

Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke

NCT01623622 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2017-02-15

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of HC-58 in patients with severe upper limb hemiplegia following stroke.

Conditions

  • Severe Upper Limb Hemiplegia

Interventions

DRUG

HC-58

once or more / week

DRUG

Placebo

once or more / week

Sponsors & Collaborators

  • Asahi Kasei Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Toshiya Umeda · Asahi Kasei Pharma Corporation Clinical Development Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623622 on ClinicalTrials.gov